

Candidate selection for development of an immunosuppressive monoclonal antibody against allergic disease

AIMEDBIO, Inc.



IMMUNOLOGY	Candidate
Product Type	Fully human IgG4
Indication	Atopic Dermatitis, Chronic rhinosinusitis with nasal polyps
Target	Immune cells overexpressing CD200R1
MoA(Mechanism of Action)	Immune agonists to boost immunosuppressive signaling effect
Competitiveness	<ul style="list-style-type: none"> • Differentiated binding site • Superior cell binding affinity • Superior efficacy in inhibiting pro-inflammatory cytokines and inducing Dok2 phosphorylation
Development Stage	Candidate
Route of Administration	Intra-venous, intra-peritoneal